Cargando…

Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis

STUDY OBJECTIVES: Sleep-related adverse effects during acute treatment with antidepressants undermine adherence and impede remission. We aimed to address subtypes of sleep-related adverse effects and depict the relationship between dose and sleep-related adverse events. METHODS: We searched PubMed,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shuzhe, Li, Pei, Lv, Xiaozhen, Lai, Xuefeng, Liu, Zuoxiang, Zhou, Junwen, Liu, Fengqi, Tao, Yiming, Zhang, Meng, Yu, Xin, Tian, Jingwei, Sun, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566234/
https://www.ncbi.nlm.nih.gov/pubmed/37422714
http://dx.doi.org/10.1093/sleep/zsad177
_version_ 1785118880253870080
author Zhou, Shuzhe
Li, Pei
Lv, Xiaozhen
Lai, Xuefeng
Liu, Zuoxiang
Zhou, Junwen
Liu, Fengqi
Tao, Yiming
Zhang, Meng
Yu, Xin
Tian, Jingwei
Sun, Feng
author_facet Zhou, Shuzhe
Li, Pei
Lv, Xiaozhen
Lai, Xuefeng
Liu, Zuoxiang
Zhou, Junwen
Liu, Fengqi
Tao, Yiming
Zhang, Meng
Yu, Xin
Tian, Jingwei
Sun, Feng
author_sort Zhou, Shuzhe
collection PubMed
description STUDY OBJECTIVES: Sleep-related adverse effects during acute treatment with antidepressants undermine adherence and impede remission. We aimed to address subtypes of sleep-related adverse effects and depict the relationship between dose and sleep-related adverse events. METHODS: We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science for double-blind randomized controlled trials of depression published before April 30th, 2023. Eligible studies reporting sleep-related adverse effects during short-term monotherapy were included. The odds ratios (ORs) for sleep-related adverse effects were addressed with network meta-analysis. A Bayesian approach was used to depict the dose-effect relationship. Heterogeneity among studies was assessed using the τ(2) and I(2) statistics. Sensitivity analyses were performed without studies featuring high risk of bias. RESULTS: Studies with 64 696 patients were examined from 216 trials. Compared to placebo, 13 antidepressants showed higher ORs for somnolence, of which fluvoxamine (OR = 6.32; 95% CI: 3.56 to 11.21) ranked the top. Eleven had higher risks for insomnia, reboxetine ranked the top (OR = 3.47; 95% CI: 2.77 to 4.36). The dose-effect relationships curves between somnolence or insomnia and dose included linear shape, inverted U-shape, and other shapes. There was no significant heterogeneity among individual studies. The quality of evidence for results in network meta-analyses was rated as very low to moderate by Grading of Recommendations Assessment, Development, and Evaluation. CONCLUSIONS: Most antidepressants had higher risks for insomnia or somnolence than placebo. The diverse relationship curves between somnolence or insomnia and dose of antidepressants can guide clinicians to adjust the doses. These findings suggest clinicians pay more attention to sleep-related adverse effects during acute treatment with antidepressants.
format Online
Article
Text
id pubmed-10566234
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105662342023-10-12 Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis Zhou, Shuzhe Li, Pei Lv, Xiaozhen Lai, Xuefeng Liu, Zuoxiang Zhou, Junwen Liu, Fengqi Tao, Yiming Zhang, Meng Yu, Xin Tian, Jingwei Sun, Feng Sleep Sleep, Health, and Disease STUDY OBJECTIVES: Sleep-related adverse effects during acute treatment with antidepressants undermine adherence and impede remission. We aimed to address subtypes of sleep-related adverse effects and depict the relationship between dose and sleep-related adverse events. METHODS: We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science for double-blind randomized controlled trials of depression published before April 30th, 2023. Eligible studies reporting sleep-related adverse effects during short-term monotherapy were included. The odds ratios (ORs) for sleep-related adverse effects were addressed with network meta-analysis. A Bayesian approach was used to depict the dose-effect relationship. Heterogeneity among studies was assessed using the τ(2) and I(2) statistics. Sensitivity analyses were performed without studies featuring high risk of bias. RESULTS: Studies with 64 696 patients were examined from 216 trials. Compared to placebo, 13 antidepressants showed higher ORs for somnolence, of which fluvoxamine (OR = 6.32; 95% CI: 3.56 to 11.21) ranked the top. Eleven had higher risks for insomnia, reboxetine ranked the top (OR = 3.47; 95% CI: 2.77 to 4.36). The dose-effect relationships curves between somnolence or insomnia and dose included linear shape, inverted U-shape, and other shapes. There was no significant heterogeneity among individual studies. The quality of evidence for results in network meta-analyses was rated as very low to moderate by Grading of Recommendations Assessment, Development, and Evaluation. CONCLUSIONS: Most antidepressants had higher risks for insomnia or somnolence than placebo. The diverse relationship curves between somnolence or insomnia and dose of antidepressants can guide clinicians to adjust the doses. These findings suggest clinicians pay more attention to sleep-related adverse effects during acute treatment with antidepressants. Oxford University Press 2023-07-09 /pmc/articles/PMC10566234/ /pubmed/37422714 http://dx.doi.org/10.1093/sleep/zsad177 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Sleep Research Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Sleep, Health, and Disease
Zhou, Shuzhe
Li, Pei
Lv, Xiaozhen
Lai, Xuefeng
Liu, Zuoxiang
Zhou, Junwen
Liu, Fengqi
Tao, Yiming
Zhang, Meng
Yu, Xin
Tian, Jingwei
Sun, Feng
Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis
title Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis
title_full Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis
title_fullStr Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis
title_full_unstemmed Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis
title_short Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis
title_sort adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis
topic Sleep, Health, and Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566234/
https://www.ncbi.nlm.nih.gov/pubmed/37422714
http://dx.doi.org/10.1093/sleep/zsad177
work_keys_str_mv AT zhoushuzhe adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT lipei adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT lvxiaozhen adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT laixuefeng adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT liuzuoxiang adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT zhoujunwen adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT liufengqi adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT taoyiming adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT zhangmeng adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT yuxin adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT tianjingwei adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis
AT sunfeng adverseeffectsof21antidepressantsonsleepduringacutephasetreatmentinmajordepressivedisorderasystemicreviewanddoseeffectnetworkmetaanalysis